Clot dissolver tPA's tardy twin could aid in stroke recovery

Researchers at Emory University School of Medicine have identified a protein released by neurons while the brain is recovering from a stroke.

The results are scheduled for publication Oct. 21 in Journal of Neuroscience.

The protein, called urokinase-type plasminogen activator or uPA, has been approved by the FDA to dissolve in the lungs. It has been tested in clinical trials in some countries as a treatment for acute stroke.

The Emory team's findings suggest that in stroke, uPA's benefits may extend beyond the time when doctors' principal goal is dissolving the clot that is depriving the brain of blood.

Instead, uPA appears to help brain cells recover from the injuries induced by loss of blood flow. Treating mice with uPA after an experimental stroke can improve their recovery of motor function, the researchers found.

uPA (urokinase-type plasminogen activator) and tPA (tissue-type plasminogen activator), the drug that is the only approved treatment for , have similar names, because they both act biochemically to activate plasmin, which directly dissolves blood clots.

"We are finding that uPA and tPA do very different things in the brain. We see that uPA is released during the recovery phase of a stroke over several hours," says lead author Manuel Yepes, MD, associate professor of neurology at Emory University School of Medicine. "This is in sharp contrast with tPA, which is released from neurons within milliseconds of hypoxia or ischemia [loss of blood flow]."

Co-first authors of the paper are postdoctoral fellows Fang Wu, PhD, and Ramiro Echeverry, MD, and pregraduate student Marcela Catano.

The Emory team found that mice that lack uPA do not regain as much forelimb strength after a one hour blockage of the middle cerebral artery, compared with control mice. This suggests that uPA produced within the brain is promoting recovery. In addition, immediate treatment with supplementary uPA after a stroke can boost the recovery of forelimb strength, the researchers found.

uPA does not have a direct effect on neurons when they are being deprived of oxygen and nutrients. Rather, uPA appears to help remodel , structures on neurons that are critical for communication. After a stroke, dendritic spines are replaced by swelling on neurons that survive but are close to the damaged area of the brain.

In cultured neurons, uPA can induce the re-emergence of dendritic spines after toxic injury that mimics the effects of a stroke. uPA seems to help the ' internal skeletons reorganize. The part of the uPA protein that acts in dissolving blood clots is not necessary for this effect, but uPA's interaction with its receptor uPAR is required.

Yepes says his team is testing whether treatment with uPA can still provide benefits in mice when it is given some time after an experimental , which could provide some hints as how it could best be used clinically.


Explore further

Biomarkers uPA/PAI-1 in breast cancer: Benefit and harm of the test unclear

More information: Outcome Evaluation of Intravenous Infusion of Urokinase for Acute Ischemic Stroke, Chonnam Med J. Apr 2012; 48(1): 52–56. Published online Apr 26, 2012. DOI: 10.4068/cmj.2012.48.1.52
Journal information: Journal of Neuroscience

Provided by Emory University
Citation: Clot dissolver tPA's tardy twin could aid in stroke recovery (2014, October 21) retrieved 18 February 2020 from https://medicalxpress.com/news/2014-10-clot-dissolver-tpa-tardy-twin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments